Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)
The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.
Metastatic Colorectal Cancer
DRUG: Anlotinib|DRUG: Placebo
Overall Survival (OS), From randomization until death (up to 24 months)
Progress free survival (PFS), each 42 days up to PD or death(up to 24 months)|Objective Response Rate (ORR), each 42 days up to intolerance the toxicity or PD (up to 24 months)|Disease Control Rate (DCR), each 42 days up to intolerance the toxicity or PD (up to 24 months)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Until 30 day safety follow-up visit
Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration（SFDA:2011L00661） which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd.To compare the effects and safety of Anlotinib with placebo in patients with metastatic colorectal cancer refractory to standard chemotherapies.